Compare ADT Inc (ADT) vs Amgen, Inc. (AMGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADT Inc vs Amgen, Inc. — how do they compare? ADT Inc trades at $6.73 (market cap $5.07B), while Amgen, Inc. trades at $368.25 (market cap $198.67B). The key difference: Amgen, Inc. is far larger — about 39.2× ADT Inc's market cap, and ADT Inc pays the higher dividend (3.18%). Which is the better fit depends on your goals.
| ADT | AMGN | |
|---|---|---|
Market Cap | $5.07B | $198.67B |
Sector | Industrials | Health |
52-Week High | $8.85 | $388.16 |
52-Week Low | $6.30 | $271.18 |
Enterprise Value | $12.62B | $243.95B |
Dividend Yield | 3.18% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADT trades at $6.91, up 1.17% today, with a bullish technical signal and consistent earnings beats. The company shows strong profitability with an 80.82% gross margin and 12.14% net margin, supported by positive news including recent industry awards and board participation in the Connectivity Standards Alliance. Cash flow from operations remains robust at $1.88 billion for 2025, though net cash flow was slightly negative.
Outlook is positive with analyst consensus leaning buy (47% buy ratings), but risks include high long-term debt of $7.51 billion and competitive pressures in home security. Revenue growth is stable, and valuation metrics like P/E of 8.88 suggest potential undervaluation, making it attractive for value-oriented investors mindful of leverage.
Amgen (AMGN) trades at $368.10, down 1.62% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net income margin of 20.96% and has beaten earnings estimates for three consecutive quarters. Recent news includes a favorable court ruling blocking a price cap on Enbrel and analyst upgrades, though regulatory challenges for Tavneos in Europe pose headwinds. Cash flow from operations remains robust at nearly $10 billion annually.
The outlook for AMGN is positive with steady revenue growth and high margins, but investors face risks from patent expirations and regulatory scrutiny. Analyst consensus is bullish with a $358.25 price target, though the current price exceeds this, suggesting near-term consolidation may occur. The company's strong cash generation supports dividend payments, but high debt levels require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
